Date: June 30, 2019
Time: 13.00 – 18.00 PST
Location: Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC
First Floor, Seminar Room #101
1425 San Pablo Street, Los Angeles, CA 90033
After the success of the 2018 CIRM/IABS “4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells” and the associated HESI CT-TRACS tumorigenicity workshop (conference report: Abbot et al. 2018), five organizations have come together to continue the discussion and address bottlenecks associated with the manufacturing and testing of pluripotent stem cell-based therapies.
The Pluripotent Stem Cells Manufacturing Meeting 2019 (PSCM2019) will be held on 30 June 2019 at the Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC (Los Angeles, California), following the International Society for Stem Cell Research (ISSCR) 2019 Annual Meeting. For more information, please contact Lucilia Mouriès (email@example.com).
This event is co-hosted by the following organizations:
Live-streaming information for the event and related materials will be available via GAiT’s website: http://www.gait.global/expert-panels-2019/
13.00-13.25 Opening Panel: Review of takeaways from the June 2018 CIRM/IABS PSC Manufacturing, Standards, & Controls meeting; objectives and context for this year’s discussion.
13.30-13.55 Panel 2: Pluripotent stem cells as manufacturing cell substrates – challenges encountered and forecast
14.00-14.25 Panel 3: International standardization of human pluripotent stem cell manufacturing – rationale and review of current status
14.30-14.55 Panel 4: Defining Quality Parameters of Human Pluripotent Stem Cells as manufacturing intermediates for therapeutic development
15.00-15.25 Panel 5: Outlining a road map to cell therapy comparability
16.00-16.25 Panel 6: Towards standardized tumorigenicity testing – challenges and the way forward
16.30-16.55 Panel 7: Towards automated and closed human Pluripotent Stem Cell Manufacture
17.00-17.15 Panel 8: Financial and Logistical Challenges to human Pluripotent Stem Cell Manufacture
17.20-17.35 Panel 9: Avoiding immunorejection and engraftment failure – challenges and the way forward
17.40-18.00 Closing Panel: Organizers summarizing and highlighting upcoming events
See more on the format and recommendations for participation here.